视网膜色素变性的分子遗传学与新兴治疗:基础研究与临床展望
目前临床试验中的治疗包括基因治疗、细胞治疗和视网膜假体;voretigene neparvovec(AAV2-hRPE65v2,Luxturna)的3期临床试验显示对RPE65介导的遗传性视网膜营养不良(包括Leber先天性黑矇和RP)有显著疗效,即将获批成为首个眼科基因治疗生物制品。尽管存在靶基因和适用患者有限、疗效中等、给药方式有创等局限,基因编辑技术和新型基因递送载体的发展使基因治疗成为RP及其他遗传性视网膜营养不良有前景的治疗方式。
要点
- RP由约70个基因的3000多种突变引起,与多种视网膜营养不良存在广泛遗传重叠。
- voretigene neparvovec的3期临床试验显示对RPE65介导的遗传性视网膜营养不良有显著疗效。
- 基因治疗受靶基因和适用患者有限、疗效中等、给药方式有创等限制。
核心结论
- 基因编辑技术和新型基因递送载体的发展使基因治疗成为RP及其他遗传性视网膜营养不良未来有前景的治疗方式。
研究设计与样本
- 综述,总结RP的分子遗传学基础及基因治疗、细胞治疗、视网膜假体等新兴治疗的基础研究与临床进展。
主要发现
- RP涉及约70个基因的3000多种遗传突变,并与其他类型视网膜营养不良存在广泛遗传重叠。
- 使用神经营养因子、抗氧化剂和抗凋亡剂等药物治疗大多未针对RP的根本病因,临床疗效尚未明确证实。
- voretigene neparvovec(AAV2-hRPE65v2,Luxturna)的3期临床试验显示对RPE65介导的遗传性视网膜营养不良(包括Leber先天性黑矇和RP)有显著疗效。
关键数值与推荐
- voretigene neparvovec(AAV2-hRPE65v2,Luxturna)即将获批成为首个眼科基因治疗生物制品。
临床怎么用
- 原文未据此给出推荐。
局限性
- 基因治疗目前存在靶基因和适用患者有限、疗效中等、给药方式有创等局限。
- 多数药物治疗未针对RP的根本病因,临床疗效尚未明确证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Retinitis Pigmentosa (RP) is a hereditary retinopathy that affects about 2.5 million people worldwide. It is characterized with progressive loss of rods and cones and causes severe visual dysfunction and eventual blindness in bilateral eyes. In addition to more than 3000 genetic mutations from about 70 genes, a wide genetic overlap with other types of retinal dystrophies has been reported with RP. This diversity of genetic pathophysiology makes treatment extremely challenging. Although therapeutic attempts have been made using various pharmacologic agents (neurotrophic factors, antioxidants, and anti-apoptotic agents), most are not targeted to the fundamental cause of RP, and their clinical efficacy has not been clearly proven. Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses. Gene therapy, a strategy to correct the genetic defects using viral or non-viral vectors, has the potential to achieve definitive treatment by replacing or silencing a causative gene. Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP. It is about to be approved as the first ocular gene therapy biologic product. Despite current limitations such as limited target genes and indicated patients, modest efficacy, and the invasive administration method, development in gene editing technology and novel gene delivery carriers make gene therapy a promising therapeutic modality for RP and other hereditary retinal dystrophies in the future.
引用
- Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 2017. PMID: 29097191. doi:10.1016/j.preteyeres.2017.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。